Figure 1 — MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway

Research Paper|Volume 11, Issue 9|pp. 2551–2564

MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133⁺ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway

Back to articleFigure 1(1 of 8)

100%

Figure 1.Cisplatin resistance of CD133⁺ HCC cells. (A) CD133⁺ HCC cells were identified by using CD133 antibody in HepG2 and Huh7 cells. (B) Purity of sorted CD133⁺ and CD133^- HepG2 and Huh7 cells was tested by flow cytometry. (C) CD133⁺ and CD133^- HepG2 and Huh7 cells were treated with different concentrations of cisplatin (0~30 μM) for 48 h. Cell viability curve was conducted by MTT assays. (D) IC50 of cisplatin to CD133⁺ and CD133^- HepG2 and Huh7 cells was calculated according to the MTT assays. *P<0.05.